Open Access Open Access  Restricted Access Subscription or Fee Access

Natural Antibodies Against Enteromicrobes and their Toxins for the Treatment of Rheumatoid Arthritis

Rashi Rai, Saba Masood, Bhupinderjit Kaur Ghai


Autoimmune diseases (ADs) are thought to be brought on by the host immune system accidentally attacking and destroying its own tissue. “Molecular mimicry,” which asserts that antibodies against an infectious agent cross-react with a self-antigen possessing an identical or similar antigenic epitope, is a generally recognised theory to explain the pathogenic mechanism of ADs. This theory, however, was probably developed using false antibody assay data that was heavily impacted by strong false positive results in immunoassay equipment. Therefore, it is strongly recommended that this hypothesis be reevaluated using an adequate blocking agent capable of removing all sorts of nonspecific reactions and an acceptable assay design. In this review, we explore the notion that reduced immune function may be the fundamental, prevalent defect in ADs, increasing vulnerability to possible GI pathogens, such as bacteria and their components or food components, that may cause the disease. The host defensive system, which is carefully regulated by “immune function,” “mucosal barrier function,” and “intestinal bacterial balance,” may also be affected by abnormalities in the host's physical state. These disruptions may set off a chain reaction that can result in persistent health issues and eventually an autoimmune illness.


Autoimmune diseases, biologic disease-modifying antirheumatic drugs, immune milk, Crohn's disease, relapsing polychondritis

Full Text:



Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best practice & research Clinical rheumatology. 2017 Feb 1;31(1):3–18.

Katayama K, Matsuno T, Waritani T, Terato K, Shionoya H. Supplemental treatment of rheumatoid arthritis with natural milk antibodies against enteromicrobes and their toxins: results of an open-labelled pilot study. Nutrition Journal. 2011 Dec;10(1):1–1.

Aoki S, Yoshikawa K, Yokoyama T, Nonogaki T, Iwasaki S, Mitsui T, Niwa S. Role of enteric bacteria in the pathogenesis of rheumatoid arthritis: evidence for antibodies to enterobacterial common antigens in rheumatoid sera and synovial fluids. Annals of the rheumatic diseases. 1996 Jun 1;55(6):363–9.

Aho K, Koskenvuo M, Tuominen J, Kaprio J. Occurrence of rheumatoid arthritis in a nationwide series of twins. The Journal of rheumatology. 1986 Oct 1;13(5):899–902.

Hogg K, Blair JD, McFadden DE, von Dadelszen P, Robinson WP. Early onset pre-eclampsia is associated with altered DNA methylation of cortisol-signalling and steroidogenic genes in the placenta. PloS one. 2013 May 7;8(5):e62969.

Bowden AP, Barrett JH, Fallow WE, Silman AJ. Women with inflammatory polyarthritis have babies of lower birth weight. The Journal of rheumatology. 2001 Feb 1;28(2):355–9.

Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. The American journal of medicine. 2007 Nov 1;120(11):936–9.

Kumar P, Banik S. Pharmacotherapy options in rheumatoid arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2013 Jan;6:CMAMD-S5558.

Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St. Clair EW, Bridges Jr SL, Zhang J, McVie T, Howard G, van der Heijde D. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis & Rheumatism. 2012 Sep;64(9):2824–35.

Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomedical reports. 2013 Mar 1;1(2):177–84.

Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)–Fc fusion protein. New England Journal of Medicine. 1997 Jul 17;337(3):141–7.

Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta‐analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2010 Apr;30(4):339–53.

Rider P, Carmi Y, Cohen I. Biologics for targeting inflammatory cytokines, clinical uses, and limitations. International journal of cell biology. 2016 Oct;2016.

Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, Jeong HS, Chung SH. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Archives of pharmacal research. 2015 May;38(5):575–84.

STAT CJ, EGF P. The Jak-STAT pathway in rheumatoid arthritis. The Journal of rheumatology. 2005;32(9):1650–3.

Ivashkiv LB, Hu X. The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective?. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2003 Aug;48(8):2092–6.

O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. New England Journal of Medicine. 2013 Jan 10;368(2):161–70.

Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 1995 Dec 1;3(6):811–21.

Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, van de Loo FA, van den Berg WB. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. The Journal of Immunology. 2001 Jul 15;167(2):1004–13.

Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature immunology. 2005 Nov;6(11):1123–32.

Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annual review of immunology. 2009 Apr 23;27:485–517.

Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. Trends in molecular medicine. 2016 Mar 1;22(3):230–41.

Elshabrawy HA, Chen Z, Volin MV, Ravella S, Virupannavar S, Shahrara S. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis. 2015 Oct;18(4):433–48.

Kennedy D, Jerosch-Herold C, Hickson M. The reliability of one vs. three trials of pain-free grip strength in subjects with rheumatoid arthritis. Journal of Hand Therapy. 2010 Oct 1;23(4):384–91.

Konisti S, Kiriakidis S, Paleolog EM. Hypoxia—a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nature Reviews Rheumatology. 2012 Mar;8(3):153–62.

Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Molecular and cellular biology. 2003 Dec 15;23(24):9361–74.

Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU. Differentiating the functional role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α (EPAS‐1) by the use of RNA interference: erythropoietin is a HIF‐2α target gene in Hep3B and Kelly cells. The FASEB Journal. 2004 Sep;18(12):1462–4.

Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proceedings of the National Academy of Sciences. 1997 Apr 29;94(9):4273–8.

Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El‐Gabalawy H. Hypoxia‐induced production of stromal cell–derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis & Rheumatism. 2002 Oct;46(10):2587–97.

Brouwer E, Gouw AS, Posthumus MD, Van Leeuwen MA, Boerboom AL, Bijzet J, Bos R, Limburg PC, Kallenberg CG, Westra J. Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis. Clin Exp Rheumatol. 2009 Nov 1;27(6):945–51.

Bennett JC. The infectious etiology of rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1978 Jun;21(5):531–8.

Olhagen B, Månsson I. Intestinal Clostridium perfringens in rheumatoid arthritis and other collagen diseases 1. Acta Medica Scandinavica. 1968 Jan 12;184(1‐6):395–402.

Gripenberg M. Common Serological Features in Rheumatoid Arthritis and Yersinia Arthritis: Demonstration of Rheumatoid Factors and Antibodies against ssDNA and Yersinia enterocolitica Lipopolysaccharide by ELISA. Scandinavian Journal of Rheumatology. 1981 Jan 1;10(2):85–91.

Ebringer A, Rashid T. Rheumatoid arthritis is an autoimmune disease triggered by Proteus urinary tract infection. Clinical and Developmental Immunology. 2006 Mar 1;13(1):41–8.

Albani S, Keystone EC, Nelson JL, Ollier WE, La Cava A, Montemayor AC, Weber DA, Montecucco C, Martini A, Carson DA. Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nature medicine. 1995 May;1(5):448–52.

Campbell B, Petersen WE. Immune milk—a historical survey. InDairy Science Abstracts 1963 Sep (Vol. 25, No. 9, pp. 345–358).

Lascelles AK. A review of the literature on some aspects of immune milk. InDairy Sci. Abstr 1963 (Vol. 25, No. 9, p. 359).

Reddy PG, Frey RA. Nutritional modulation of immunity in domestic food animals. Advances in Veterinary Science and comparative medicine. 1990 Jan 1;35:255-81.

Goldman AS. The immune system in human milk and the developing infant. Breastfeeding Medicine. 2007 Dec 1;2(4):195–204.

Boesman-Finkelstein M, Finkelstein RA. Bovine lactogenic immunity against pediatric enteropathogens. Immunology of Milk and the Neonate. 1991:361–7.

Kushnareva MV, Keshishian ES, Soboleva SV. The efficacy of using an immune lactoglobulin preparation for correcting intestinal dysbacteriosis in newborn infants. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii. 1995 Mar 1(2):101–4.

Goldman AS, Garza C, Schanler RJ, Goldblum RM. Molecular forms of lactoferrin in stool and urine from infants fed human milk. Pediatric research. 1990 Mar;27(3):252–5.

Kobayashi T, Ohmori T, Yanai M, Kawanishi G, Yoshikai Y, Nomoto K. Protective effect of orally administering immune milk on endogenous infection in X-irradiated mice. Agricultural and Biological Chemistry. 1991 Sep 1;55(9):2265–72.

Ishida A, Yoshikai Y, Murosaki S, Kubo C, Hidaka Y, Nomoto K. Consumption of milk from cows immunized with intestinal bacteria influences age-related changes in immune competence in mice. The Journal of nutrition. 1992 Sep 1;122(9):1875–83.

Ouwehand AC, Kirjavainen PV, Shortt C, Salminen S. Probiotics: mechanisms and established effects. International dairy journal. 1999 Jan 1;9(1):43–52.

Bitzan MM, Gold BD, Philpott DJ, Huesca M, Sherman PM, Karch H, Lissner R, Lingwood CA, Karmali MA. Inhibition of Helicobacter pylori and Helicobacter mustelae binding to lipid receptors by bovine colostrum. Journal of Infectious Diseases. 1998 Apr 1;177(4):955–61.

Katayama K, Kon Y, Okubo T, Fukai R, Makino Y, Ito H. AB0490 Evaluation of inhibitory factor of radiographic progression by iguratimod add-on therapy in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs.

Hurley WL, Theil PK. Perspectives on immunoglobulins in colostrum and milk. Nutrients. 2011 Apr 14;3(4):442–74.

Sullivan AL, Prendergast RA, Antunes LJ, Silverstein AM, Tomasi TB. Characterization of the serum and secretory immune systems of the cow and sheep. The Journal of Immunology. 1969 Aug 1;103(2):334–44.

Terato K, Do CT, Shionoya H. Slipping through the cracks: linking low immune function and intestinal bacterial imbalance to the etiology of rheumatoid arthritis. Autoimmune diseases. 2015 Mar 12;2015.



  • There are currently no refbacks.